Alterity Therapeutics Limited (ATHE)
NASDAQ: ATHE · Real-Time Price · USD
5.70
+0.21 (3.83%)
At close: Jul 8, 2026, 4:00 PM EDT
5.68
-0.02 (-0.35%)
After-hours: Jul 8, 2026, 6:32 PM EDT
Alterity Therapeutics Revenue
Alterity Therapeutics had revenue of 2.80M AUD in the half year ending December 31, 2025, with 47.49% growth. This brings the company's revenue in the last twelve months to 8.84M, up 137.32% year-over-year. In the fiscal year ending June 30, 2025, Alterity Therapeutics had annual revenue of 7.64M with 90.12% growth.
Revenue (ttm)
8.84M AUD
Revenue Growth
+137.32%
P/S Ratio
20.89
Revenue / Employee
982,113 AUD
Employees
9
Market Cap
92.46M USD
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 7.64M | 3.62M | 90.12% |
| Jun 30, 2024 | 4.02M | 102.96K | 2.63% |
| Jun 30, 2023 | 3.92M | -1.21M | -23.56% |
| Jun 30, 2022 | 5.12M | 638.30K | 14.23% |
| Jun 30, 2021 | 4.49M | 4.36M | 3,554.58% |
| Jun 30, 2020 | 122.73K | -4.83M | -97.52% |
| Jun 30, 2019 | 4.95M | 1.83M | 58.40% |
| Jun 30, 2018 | 3.13M | 103.11K | 3.41% |
| Jun 30, 2017 | 3.02M | -1.87M | -38.27% |
| Jun 30, 2016 | 4.90M | -1.60M | -24.61% |
| Jun 30, 2015 | 6.49M | -1.71M | -20.89% |
| Jun 30, 2014 | 8.21M | 3.57M | 76.95% |
| Jun 30, 2013 | 4.64M | 2.11M | 83.56% |
| Jun 30, 2012 | 2.53M | 2.36M | 1,451.39% |
| Jun 30, 2011 | 162.92K | -52.09K | -24.23% |
| Jun 30, 2010 | 215.01K | -213.19K | -49.79% |
| Jun 30, 2009 | 428.19K | -62.92K | -12.81% |
| Jun 30, 2008 | 491.11K | -16.32K | -3.22% |
| Jun 30, 2007 | 507.44K | -542.85K | -51.69% |
| Jun 30, 2006 | 1.05M | -1.60M | -60.41% |
| Jun 30, 2005 | 2.65M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Black Diamond Therapeutics | 70.00M |
| Verrica Pharmaceuticals | 37.16M |
| Atara Biotherapeutics | 23.14M |
| Cibus | 4.29M |
| NeOnc Technologies Holdings | 39.99K |
ATHE News
- 1 day ago - Alterity Therapeutics receives FDA meeting minutes on pathway for ATH434 - TheFly
- 1 day ago - Alterity Therapeutics Receives FDA End-of-Phase 2 Meeting Minutes Confirming Registrational Pathway for ATH434 in Multiple System Atrophy - GlobeNewsWire
- 9 days ago - Alterity Therapeutics initiated with a Buy at JonesResearch - TheFly
- 22 days ago - Alterity Therapeutics assumed with a Buy at Ladenburg - TheFly
- 23 days ago - Alterity Therapeutics Slides: Corporate presentation - Filings
- 4 weeks ago - Alterity Aligns With FDA On Phase 3 Design For ATH434 In Treating Multiple System Atrophy - Nasdaq
- 4 weeks ago - Alterity Therapeutics (ATHE) Gets FDA Nod for Phase 3 Program - GuruFocus
- 4 weeks ago - Alterity Therapeutics (ATHE) Secures FDA Agreement for Phase 3 ATH434 Trial - GuruFocus